Sanofi (SNY)
Pre-Market:
| Previous Close | 48.54 |
| Open | 48.43 |
| Bid | 47.89 x 400 |
| Ask | 47.96 x 500 |
| Day's Range | 47.80 - 48.47 |
| 52 Week Range | 42.63 - 55.72 |
| Volume | |
| Avg. Volume | 2,016,652 |
| Market Cap | 121.886B |
| Beta (5Y Monthly) | 0.44 |
| PE Ratio (TTM) | 24.84 |
| EPS (TTM) | 1.93 |
| Earnings Date | Jul 25, 2024 |
| Forward Dividend & Yield | 2.04 (4.20%) |
| Ex-Dividend Date | May 09, 2024 |
| 1y Target Est | 59.90 |
Simply Wall St.3 High-Yielding Dividend Stocks On Euronext Paris With Up To 4.2% Yield
In recent trading sessions, France's CAC 40 Index has experienced a modest decline of 0.89%, reflecting broader European market uncertainties and mixed signals regarding future interest rate cuts. Amidst this backdrop, dividend stocks on Euronext Paris continue to attract attention for their potential to offer investors steady income streams in a fluctuating market environment. A key consideration for selecting strong dividend stocks involves not just the yield but also the sustainability...
ZacksSanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.
GlobeNewswirePress Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase 3 study If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care treatment for patients with newly diagnosed transplant-ineligible multiple myeloma Pivotal IMROZ phase 3 study results to be featured during oral presentation at the 2024 American Society of Clinical Oncolog
